Is there a Bearish outlook for ABIOMED, Inc. (NASDAQ:ABMD) this week?

May 13, 2018 - By Winifred Garcia

ABIOMED, Inc. (NASDAQ:ABMD) LogoInvestors sentiment decreased to 1.18 in 2017 Q4. Its down 0.12, from 1.3 in 2017Q3. It turned negative, as 19 investors sold ABIOMED, Inc. shares while 110 reduced holdings. 55 funds opened positions while 97 raised stakes. 36.44 million shares or 5.39% less from 38.51 million shares in 2017Q3 were reported.
Moreover, Artemis Inv Llp has 0.09% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 30,098 shares. Finance Architects Inc owns 2,000 shares or 0.06% of their US portfolio. Cap Fund Mngmt holds 11,320 shares. Dorsey Wright invested 1.45% in ABIOMED, Inc. (NASDAQ:ABMD). Oak Ridge Invests Ltd holds 0.93% or 104,119 shares in its portfolio. 23,812 are held by Balyasny Asset Management Ltd. Parametric Associate Limited Liability Corporation has 0.01% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 49,992 shares. Pennsylvania-based Sei Invs has invested 0.09% in ABIOMED, Inc. (NASDAQ:ABMD). Cibc Bank & Trust Usa holds 0.04% in ABIOMED, Inc. (NASDAQ:ABMD) or 1,550 shares. Arcadia Mngmt Corporation Mi holds 0.03% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 537 shares. Us National Bank & Trust De reported 2,578 shares. Primecap Ca accumulated 0.59% or 4.08M shares. Beaumont Financial Ptnrs Limited Company accumulated 0.06% or 2,550 shares. Loomis Sayles And Lp holds 0.01% or 31,101 shares. Global X Mgmt Limited Liability Company owns 452 shares.

Since February 20, 2018, it had 0 buys, and 5 selling transactions for $31.65 million activity. Another trade for 13,500 shares valued at $4.70 million was sold by PUHY DOROTHY E. On Monday, May 7 the insider Howley Michael G sold $6.09M. 22,790 shares were sold by BOLT WILLIAM J, worth $7.93M. 21,890 shares were sold by SUTTER MARTIN P, worth $7.52 million.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 8 analysts covering Abiomed (NASDAQ:ABMD), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Abiomed had 12 analyst reports since December 21, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Friday, February 16 by SunTrust. The firm has “Buy” rating given on Friday, February 2 by Stephens. The stock has “Buy” rating by Jefferies on Thursday, December 21. Guggenheim maintained the stock with “Buy” rating in Friday, February 2 report. The firm has “Buy” rating given on Thursday, January 4 by Piper Jaffray. The stock has “Equal-Weight” rating by Morgan Stanley on Tuesday, May 1. Jefferies maintained the shares of ABMD in report on Thursday, February 1 with “Buy” rating. Piper Jaffray maintained the shares of ABMD in report on Thursday, February 1 with “Buy” rating. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Equal-Weight” rating given on Friday, February 2 by Morgan Stanley. Stephens maintained the shares of ABMD in report on Monday, April 9 with “Buy” rating. Below is a list of ABIOMED, Inc. (NASDAQ:ABMD) latest ratings and price target changes.

01/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $259 New Target: $320 Maintain
09/04/2018 Broker: Stephens Rating: Buy New Target: $300.0000 Maintain
04/04/2018 Broker: Goldman Sachs Rating: Buy New Target: $332 Initiates Coverage On
16/02/2018 Broker: SunTrust Rating: Buy New Target: $370.0 Maintain
02/02/2018 Broker: Stephens Rating: Buy New Target: $274.0 Maintain
02/02/2018 Broker: Leerink Swann Rating: Buy New Target: $300.0
02/02/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $204 New Target: $259 Maintain
02/02/2018 Broker: Guggenheim Rating: Buy New Target: $280.0 Maintain
01/02/2018 Broker: Jefferies Rating: Buy New Target: $300.0 Maintain
01/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $300.0 Maintain

The stock increased 1.03% or $3.8 during the last trading session, reaching $372.68. About 560,298 shares traded or 15.09% up from the average. ABIOMED, Inc. (NASDAQ:ABMD) has risen 128.67% since May 13, 2017 and is uptrending. It has outperformed by 117.12% the S&P500.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $16.54 billion. It also provides continuum of care to heart failure patients. It has a 186.99 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Nasdaq.com which released: “Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33 …” on May 03, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” published on May 11, 2018, Seekingalpha.com published: “ABIOMED (ABMD) Q4 2018 Results – Earnings Call Transcript” on May 03, 2018. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: Benzinga.com and their article: “Abiomed Earnings Outlook” published on May 02, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” with publication date: May 10, 2018.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


WP Twitter Auto Publish Powered By : XYZScripts.com